Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

P. A. Zucali, M. Simonelli, G. Michetti, M. Tiseo, G. L. Ceresoli, E. Collovà, A. Follador, M. Lo Dico, A. Moretti, F. De Vincenzo, E. Lorenzi, M. Perrino, L. Giordano, G. Farina, A. Santoro, M. Garassino

Research output: Contribution to journalArticle

Abstract

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (

Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalLung Cancer
Volume75
Issue number3
DOIs
Publication statusPublished - Mar 2012

Keywords

  • Disease control
  • Malignant pleural mesothelioma
  • Pemetrexed
  • Progression-free survival
  • Re-treatment
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey'. Together they form a unique fingerprint.

  • Cite this